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Introduction: Rosai–Dorfman disease (RDD) is a rare proliferative histiocytic disorder of unknown etiology. RDD
typically presents with generalized lymphadenopathy and polymorphic histiocytic infiltration of the lymph node sinuses;
however, occurrences of extranodal soft tissue RDD may rarely occur when masquerading as a soft tissue sarcoma.
Materials and methods: A comprehensive search of all published cases of soft tissue RDD without associated
lymphadenopathy was conducted using PubMed and Google Scholar for the years 1988 to 2011. Ophthalmic RDD
was excluded.
Results: Thirty-six cases of extranodal soft tissue RDD, including the current one, have been reported since 1988.
Anatomical distribution varied among patients. Four (11.1%) patients presented with bilateral lesions in the same
anatomic region. Pain was the most common symptom in six (16.8%) patients. Sixteen (41.6%) patients were managed
surgically, of which one (2.8%) case experienced recurrence of disease.
Conclusion: RDD is a rare inflammatory non-neoplastic process that should be considered in the differential diagnosis
of a soft tissue tumor. Thus, differentiation of extranodal RDD from more common soft tissue tumors such as soft tissue
sarcoma or inflammatory myofibroblastic tumor is often difficult and typically requires definitive surgical excision with
histopathological examination. While the optimal treatment for extranodal RDD remains ill-defined and controversial,
surgical excision is typically curative.
Keywords: Rosai–Dorfman disease soft tissue, Rosai–Dorfman disease cutaneous, Sinus histiocytosis with massive
lymphadenopathyBackground
Sinus histiocytosis with massive lymphadenopathy
(SHML) is a class II histiocytosis first described as a
unique clinicopathologic entity by Rosai and Dorfman in
1969 [1]. Although lymph nodes are more commonly in-
volved, any organ may be affected – thus the term RDD
has been adopted in place of SHML [1]. A rare disease,
RDD is distributed worldwide, predominantly affecting
young people and with a slight male predominance [2].
The disease typically presents with bilateral painless
lymphadenopathy of the head and neck as well as fever,
leukocytosis, elevated erythrocyte sedimentation rate
and polyclonal hypergammaglobulinemia [3,4]. Extranodal* Correspondence: rchamberlain@barnabashealth.org
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distribution, and reproduction in any mediumpresentations have also been described, with the most
common sites including skin and nasal sinuses [4]. RDD is
considered a non-neoplastic manifestation with a self-
limited course; however, it may also undergo exacerba-
tions and remissions rendering treatment to be necessary
[2]. Histologically, RDD classically shows an inflammatory
infiltrate rich in lymphocytes, plasma cells and large his-
tiocytes [4]. RDD histiocytes are unique because they
phagocytose intact lymphocytes and other immune cells, a
histological hallmark of the disease termed emperipolesis
[5]. The largest report of RDD (1969) involved 423 cases,
with 182 patients having extranodal disease [3]. Only 13
patients in this series presented with soft-tissue RDD with-
out detectable lymphadenopathy [3]. Here we describe an
unusual case of RDD in a middle-aged African American
female presenting as a painful right medial thigh mass.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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A 56-year-old African American female presented to the
Saint Barnabas Medical Center (Livingston, NJ, USA) with
a 1-year history of an enlarging painful right medial thigh
mass. Her medical history was significant for hyperten-
sion, diabetes, hypercholesterolemia, degenerative disk
disease and asthma. The mass was noted to be extremely
painful and was located anterior and superficial to the ad-
ductor muscle group in the right medial thigh. The patient
reported a pulling, painful sensation in the knee joint
as well as discomfort upon standing for long periods
of time. She denied any constitutional symptoms and had
no reported neurological deficits. No weight loss was re-
ported. A chest, abdomen, and pelvis computed tomog-
raphy scan was performed, demonstrating no systemic
adenopathy. A magnetic resonance imaging study of the
right lower extremity was obtained and revealed a 7 cm ×
5 cm × 3.2 cm ill-defined, enhancing soft tissue mass, sus-
picious for a soft tissue sarcoma located in the deep sub-
cutaneous tissues of the right thigh, adjacent to the vastus
medialis muscle (Figure 1). The lesion was suspicious for a
primary malignancy/sarcoma and the patient underwent a
core biopsy of the lesion. Biopsy results showed an in-
flammatory mass most consistent with an inflammatory
myofibroblastic tumor. However, the tissue sample was
limited and a diagnosis of sarcoma could not be excluded.
An incisional biopsy was then completed that demon-
strated an inflammatory pseudotumor with mesenchymalFigure 1 Large radiolucent mass in the right medial thigh. T1-
weighted transverse magnetic resonance image of the right lower
extremity demonstrating a large radiolucent mass in the right
medial thigh (black arrow).fatty and fibroblastic proliferation and prominent inflam-
matory cell infiltration. There was no evidence of any
atypia or identifiable lymphoma. The mass was positive
for Vimentin and BCL-2, and was negative for all other
markers including desmin, smooth muscle actin, CD34,
AE1, S-100, p53 ALK-1 and EBER-RNA. The patient’s
symptoms progressed and a wide local excision of the
mass was completed.
On gross examination, the specimen weighed 357 g.
There was an ill-defined, firm, yellow to tan mass deep
within the subcutaneous tissue that measured 8 cm ×
7.5 cm × 6 cm. The mass had a fleshy cut surface. There
were no overlying skin changes. Microscopic examination
demonstrated a mixed inflammatory background includ-
ing lymphocytes, plasma cells, polymorphonuclear leuko-
cytes and small areas of bland fibroblasts (Figure 2a,b).
There were large aggregates of pale-staining histiocytes
demonstrating emperipolesis (Figure 2c). Immunohisto-
chemical stains for S-100 and CD68 were strongly positive
(Figure 3a,b) in the histiocytes. Fluorescence in situ
hybridization was negative for MDM2 gene amplification,
excluding a well-differentiated liposarcoma. The above
immunophenotype and characteristic histological findings
of emperipolesis were consistent with a final pathologic
diagnosis of extranodal RDD.
Postoperatively the patient had experienced persistent
but resolving right medial thigh pain and was referred for
physiotherapy. At the patient’s 9-month follow-up, there
was no recurrence of the tumor on the right side and the
painful symptoms were resolving. However, she then
presented with a relatively nontender 2 cm × 4 cm cyst-
like mass on the left medial thigh in the popliteal region.
Magnetic resonance imaging demonstrated a 5.3 cm × 4
cm × 1.6 cm area consistent with either a lymphangioma
or resolving necrosis from a residual mass. Core biopsy re-
sults yielded extranodal RDD with cells positive for S-100,
CD68 and CD117. The sample was negative for AE1/3
and CD34. CD1a testing was not performed on the core
biopsy. An excisional biopsy was performed and on gross
examination the specimen was a fragment of tan–yellow
adipose tissue measuring 7 cm × 6 cm × 1.5 cm, with a
poorly defined tan-colored region of induration measuring
2 cm × 1.2 cm × 1 cm. Microscopic examination was once
again consistent with extranodal RDD confirmed with im-
munohistochemical stains (positive for S-100 and CD68).
CD1a immunohistochemical staining was not performed
on the excisional biopsy tissue.
Results
A comprehensive search of all published cases of soft
tissue RDD without associated lymphadenopathy was
conducted using PubMed and Google Scholar for the
years 1988 to 2011. Ophthalmic RDD was excluded.
Among reported cases of Rosai–Dorfman tumors, 43% of
a b c
Figure 2 Microscopic examination of right medial thigh mass demonstrating characteristic emperipolesis. (a) Groups of lymphoid
aggregates (black arrow) and scattered pale areas of fibroadipose tissue (H & E stain, original magnification ×10). (b) Histiocytes and
multinucleated cells among mixed inflammatory cells that include plasma cells and lymphocytes (H & E stain, original magnification ×20). (c)
Histiocytes engulfing lymphocytes and plasma cells (emperipolesis) (H & E stain, original magnification ×40).
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adenopathy; however, only 3% of the patients had soft tis-
sue RDD without detectable lymph node involvement
[3,5,6]. Overall, 36 cases of extranodal soft tissue RDD
had been documented since 1969, including the current
case. Clinical and treatment data for all reported soft tis-
sue RDD are detailed in Table 1. Among these 36 pa-
tients, 17 (47.2%) patients were male and 19 (52.7%)
patients were female (male:female ratio, 0.89:1). The
overall mean age was 45.3 years (range 10 months to 72
years), with a mean age for males and females of 45.8 and
47.0 years, respectively. The most common anatomic lo-
cation for extranodal soft tissue RDD was the lower ex-
tremity (38.9%), followed by the upper extremity (36.1%),
the torso (36.1%) and the head and neck (19.4%). Many
patients (41.6%) presented with multiple lesion sites, with
much fewer (11.1%) presenting with bilateral lesions in
the same anatomic region. Pain was the most commonly
reported symptom (16.8%). Surgical resection was de-
scribed in 16 cases (41.6%), of which only one case (2.8%)
experienced recurrence of disease. The remaining 19
cases (52.8%) were managed medically with dapsone, ste-
roids or observation. Of these patients, some patients
(11.1%) experienced spontaneous resolution, other cases
(13.9%) had partial regression, while no changes were ob-
served in seven (19.4%) cases and one patient (2.8%)Figure 3 Immunohistochemical staining of the right medial thigh ma
(original magnification ×20).experienced regrowth of the tumor. Of the reported
cases, three patients (8.3%) had no reported follow-up
while one case (2.8%) did not report treatment. Among
cases in which immunohistochemistry was performed, 34
cases (94.4%) were reactive to S-100 stain and 30 cases
(83.3%) were reactive to CD68 stain.
Discussion
A class II histiocytosis, RDD was first described as a dis-
tinct clinicopathologic entity by Rosai and Dorfman in
1969 [1]. A rare disease, RDD is distributed worldwide
with 80% of cases occurring in children and young adults
[16]. RDD exhibits a slight male predominance (58%) and
a general predilection for individuals of African descent
[16]. The largest study of RDD was conducted by Foucar,
Rosai and Dorfman in 1990 and included 423 cases with a
histopathological diagnosis of RDD [3].
RDD is of unknown etiology, although viral agents such
as human herpes virus-6 and Epstein–Barr virus are
thought to play a role in the pathogenesis via immune sys-
tem dysregulation [17,18]. Levine and colleagues detected
human herpes virus-6 via in situ hybridization in seven of
nine SHML cases, while Luppi and colleagues had
demonstrated human herpes virus-6 antigen expression
by abnormal histiocytes [19,20]. Both sets of data sug-
gested a causative role for human herpes virus-6 virus.ss. Immunohistochemical stains are positive for (a) S-100 and (b) CD68
Table 1 Results of all published reports of extranodal soft tissue Rosai Dorfman disease (1988 to 2012)
Case Study Location Age
(years)
Sex Presenting symptoms IHC Sur al
exc n
Status after diagnosis and treatment
1 Suster et al,
1988 [7]
Lateral upper right arm and
middle third of left thigh
72 F Multiple firm flesh-colored subcutaneous nodules S-100+ No 7 years; spontaneous resolution
2 Rasool et al,
1996 [8]
Right index finger 10 mo F Right index finger swelling, pain, axilla, axillary lymph
node
NR Yes 14 months, no recurrence
3 Govender et al,
1997 [9]
Chest wall 34 F Superficial firm mass S-100+ Yes 6 months, no recurrence
CD68+
4 Child et al, 1998
[10]
Posterior left thigh 36 F Hyperpigmented indurated plaque with multiple
nodules, occasional pain
S-100+ No 12 months; no new lesions, new nodules
within plaque
CD68+
5 Quaglino et al,
1998 [11]
Skin of arms and buttocks 70 F Nodules on arms, face, buttock S-100+ NR NR
CD1a–
6 Huang et al,
2001 [12]
Medial right upper arm 43 F Numbness and paresthesias of forearm and wrist S-100+ Yes 12 months; no recurrence, mild hypoesthesia
over lesion site
CD68+
7 Stefanato et al,
2002 [13]
Upper back, thighs, feet 55 F Firm reddish brown dome-shaped papules with a single
episode of belpharoconjunctivitis
S-100+ No 24 months; spontaneous resolution
CD1a–
8 Yoon et al, 2005
[5]
Left ankle, right forearm and
arm
36 M Nontender mobile nodules, left ankle pain, epistaxis S-100+ Yes 4 months; recurrence in right maxillary sinus
9 Kong et al, 2007
[1]
Upper right arm 55 M Flat-topped papules and nodules S-100+ No 55 months; spontaneous resolution
CD68+
10 Kong et al, 2007
[1]
Left thigh and back 65 M Brown plaque and nodules S-100+ No 31 months; partial regression
CD68+
11 Kong et al, 2007
[1]
Left thigh 49 F Red to brown nodules, tenderness S-100+ No 31 months; partial regression
CD68+
12 Kong et al, 2007
[1]
Left chest 51 M Pinkish papules S-100+ Yes 28 months; no recurrence at original site but
appearance of papules in popliteal area
CD68+
13 Kong et al, 2007
[1]
Left upper back 52 M Red to dark-red papules, pruritis S-100+ No 27 months; spontaneous resolution
CD68+
14 Kong et al, 2007
[1]
Lower back 45 M Clusters of pinkish papules S-100+ Yes 26 months; no recurrence
CD68+
15 Kong et al, 2007
[1]
Upper left arm 52 F Red to brownish plaque with scattered papules and
nodules
S-100+ Yes 8 months, no recurrence
CD68+
CD1a+
16 Kong et al, 2007
[1]
Right thigh and left calf 55 M Hyperpigmented infiltrated plaque with papules
surrounding





















Table 1 Results of all published reports of extranodal soft tissue Rosai Dorfman disease (1988 to 2012) (Continued)
17 Kong et al, 2007
[1]
Left arm and right thigh 70 F Erythematous papuloplaques with papulovesicles and
pustules, pruritis
S-100+ No 24 months; partial regression
CD68+
18 Kong et al, 2007
[1]
Left arm and sacral back 48 M Pinkish to red papules S-100+ No NR
CD68+
19 Kong et al, 2007
[1]
Left thigh 49 F Brownish indurated plaque with satellite papules S-100+ No 24 months; persistence
CD68+
20 Kong et al, 2007
[1]
Left thigh and back 43 M Confluent papules and erythematous plaque S-100+ Yes 7 months; no recurrence
CD68+
21 Kong et al, 2007
[1]
Right thigh 45 M Plane hyperpigmented plaque S-100+ Yes 15 months; no recurrence
CD68+
22 Kong et al, 2007
[1]
Suprasternal fossa and sacral
back
56 F Two dome-shaped, exophytic masses surrounded by
few small papules, ulceration formed in one lesion
S-100+ Yes 15 months; no recurrence
CD68+
23 Kong et al, 2007
[1]
Right upper back 47 M Single dark-red nodule S-100+ Yes 14 months; no recurrence
CD68+
24 Kong et al, 2007
[1]
Abdomen and right buttock 21 M Confluent papules and infiltrated plaque dotted with
brownish papules
S-100+ No 12 months; slowly growing
CD68+
25 Kong et al, 2007
[1]
Upper right arm 42 M Grouped pinkish papules, pain of wrist and shoulder S-100+ No 11 months; persistence
CD68+
26 Kong et al, 2007
[1]
Face, buttock, abdomen and
bilateral lower extremities
22 F Multiple coalescing nodules, erythematous patches and
plaques, some with tumorous appearance, pruritis
S-100+ No NR
CD68+
27 Kong et al, 2007
[1]
Cheek, back and buttock 54 M Dark-red and brownish nodules S-100+ No NR
CD68+
28 Kong et al, 2007
[1]
Upper left arm 52 F Single subcutaneous mass, fever S-100+ Yes 9 months, no recurrence
CD68+
29 Kong et al, 2007
[1]
Right cheek 40 M Erythematous papuloplaque S-100+ No 6 months; partial regression
CD68+
30 Kong et al, 2007
[1]
Right cheek 52 F Erythematous papuloplaque S-100+ No 5 months; persistence
CD68+
31 Kong et al, 2007
[1]
Left cheek and neck 38 M Erythematous papuloplaque S-100+ No 2 months; persistence
CD68+
32 Penna Costa et
al, 2009 [3]
Left paravertebral mass in
posterior mediastinum





















Table 1 Results of all published reports of extranodal soft tissue Rosai Dorfman disease (1988 to 2012) (Continued)
33 Potts et al, 2008
[2]
Right forearm 31 F Firm, hyperpigmented mass NR Yes 8 months; recurrence
7 months after re-excision; no recurrence
34 Molina-Garrido
et al, 2011 [14]
Parieto-occipital cutaneous
lesion




35 Shi et al, 2011
[15]
Face, neck extremities 45 F Nonpruiginous papulonodular plaques S-100+ No 5 weeks; partial regression
CD68+/–
CD1a–
36 Current study Medial right thigh; Medial left
thigh
56 F Enlarging mass, knee joint pain S-100+ Yes 9 months; no recurrence on right but new
lesion on left
CD68+
Totals: Mean age 46.3 years (10 months to 72 years); 17 male (M):19 female (F). Surgical excision: 16 yes, 19 not reported (NR).
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DNA by in situ hybridization; however, this was detected
in only one of nine SHML cases, suggesting that Epstein–
Barr virus infection is probably not causative but may be a
contributing factor to the development of RDD [9]. Yoon
and colleagues had theorized that the initiation of mono-
cyte colony-stimulating factor-mediated histoproliferation
in RDD is an abnormal reaction of the hematolymphoid
system to infection, leading to a high level of immune acti-
vation and subsequent cytosis [5]. However, the pathogen-
esis of RDD is still poorly understood but is likely
multifactorial, with many of the documented patients
having a variety of coexisting immunologically mediatedTable 2 Clinical features of Rosai-Dorfman disease and other




Rare 0.5 to 5.4
Male:female ratio 1.33:1 2:1
Racial predilection African American Caucasian
Most common age
range at diagnosis
20.6 years 0 to 15 years
Anatomic location Cervical lymph nodes > skin >

















Extranodal disease: tumors in
skin, upper respiratory tract,
bone with or without
lymphadenopathy
Both: fever, weakness, weight
loss, anemia, shortness of
breath, headaches, nosebleeds
Pathology Capsular lesion with large
nuclei, inflammatory infiltrate
rich in lymphocytes, plasma
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S-100, protein 100% soluble in ammonium sulfate; CD68, cluster of differentiation 6
cluster of differentiation 54; CD58, cluster of differentiation 58.disorders such as asthma, systemic lupus erythematosus,
rheumatoid arthritis and hemolytic anemia [2,21].
RDD is classified as either nodal or systemic (cutane-
ous, respiratory and/or osseous). RDD typically presents
insidiously with generalized lymphadenopathy and a
polymorphic histiocytic infiltration of the lymph node si-
nuses. The cervical lymph nodes are most commonly af-
fected, followed by inguinal, axillary and mediastinal
lymph node basins [18]. RDD may mimic a more malig-
nant prognosis; however its clinical course varies from
spontaneous regression to progressive lymphadenopathy
and prolonged phases of stable disease [18,22]. Although
a rare complication, death is usually a result of nodularcommon and uncommon soft tissue tumors
istiocytosis Inflammatory
myofibroblastic tumor [26]
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organ function. Complications leading to death are other-
wise not well described among existing reports [18].
Systemic RDD is more prevalent and is characterized by
tumors at other sites such as bone, upper respiratory tract,
skin and retro-orbital tissue [23]. The cutaneous form in-
volves only the skin and adjacent soft tissue without asso-
ciated involvement of lymph nodes or other organs [2].
The cutaneous form occurs in one-third of cases, with
skin and head and neck being the most commonly af-
fected sites [17].
The differential diagnosis for RDD is challenging and is
based on clinical features as well as immunohistological
analysis and radiographic features. Lymph nodes tend to
be hypermetabolic and positive on positron emission
tomography. Upwards of 80% of patients demonstrate
polyclonal hypergammaglobulinemia and as many as 65%
have a hypochromic or normochromic normocytic anemia
[16]. Histologically, RDD is characterized by an accumula-
tion of proliferating histiocytes primarily in the sinusoids
of lymph nodes [5]. RDD histiocytes phagocytose intact
lymphocytes and other immune cells, leading to the dis-
ease’s histological hallmark finding of emperipolesis [5].
Immunohistochemically, RDD is typically positive for S-
100 and CD68 antigens and negative for CD1a antigens
[24]. However, it is important to note that CD1a reactivity
is more typical of Langerhans cell histiocytosis (LCH)
while S-100 reactivity is more characteristic of RDD [6].
While computed tomography and magnetic resonance
imaging are not diagnostic of RDD, they can exclude other
possible diagnoses as well as being useful to assess local
disease extension [18].
The differential diagnoses of RDD-type lesions include
lymphoreticular malignancies when cervical lymphaden-
opathy is present or soft tissue sarcomas when patients
present with extranodal disease. Table 2 details a com-
parison of the demographics, presenting symptoms, and
histological appearance of RDD, LCH, inflammatory
myofibroblastic tumor and soft tissue sarcoma. A lack of
cytologic atypia typically dispels more malignant diagno-
ses, and immunohistochemistry profiles will demonstrate
a macrophage-induced histiocytosis with emperipolesis
[28]. It is also important to clearly distinguish RDD-
similar S-100-positive histiocytoses such as malignant
histiocytosis and LCH [1]. Malignant histiocytosis dem-
onstrates marked cytologic atypia as well as high mitotic
activity, while LCH tends to be CD1a positive with micro-
scopic evidence of Birbeck granules [1]. In addition,
neither malignant histiocytosis nor LCH demonstrate the
hallmark finding of emperipolesis [1]. The more rare
reticulohistiocytoma may be S-100-positive; however,
this disease shows prominent ground glass appear-
ance, abundant periodic acid Schiff-positive stain and
fewer inflammatory cells in the background. Thesemarker-specific differences are useful in providing a
definitive diagnosis.
Soft tissue RDD is particularly challenging to diagnose
since it is often difficult to discern the exact morphology
of soft tissue samples. Extranodal soft tissue RDD usually
demonstrates a spindled morphology with abundant colla-
gen deposition resulting in the hallmark emperipolesis
to become more inconspicuous [6]. Furthermore, the
whorled pattern that is typically seen in soft tissue RDD
can also mislead clinicians to diagnose either benign or
malignant fibrohistiocytosis [6]. In general, however, cells
of soft tissue fibrohistiocytic lesions, such as benign fi-
brous histiocytoma or dermatofibrosarcoma protuberans,
usually have a higher nuclear to cytoplasmic ratio, more
hyperchromatic nuclei and a more distinctive whorled pat-
tern than those of soft tissue RDD [6].
Due to the rarity of the disease and its self-limited
course, no treatment protocol has been established for
RDD [18]. In symptomatic cases where the disease does
not resolve spontaneously, surgical excision is typically
performed. Symptomatic cases respond to steroids, alkyl-
ating agents and IFNα, all with varying success rates [29].
The role of radiotherapy is still poorly understood, with
some reports describing full resolution while others
showed no response [18,22].
Although RDD in extremities had been described in a
limited number of cases, this case highlighted the im-
portance of better differentiation from more common
malignancies. The painful symptoms experienced both
before and after resection in the current case were un-
characteristic, as most patients with extranodal RDD had
experienced pain-free results following resection. Fur-
thermore, the development of bilateral disease in a differ-
ent site had been only rarely reported [1,5,14,16].
Conclusions
In summary, a defined treatment strategy for RDD has
not been well described, given the rarity of the lesions
and the difficulty in diagnosing them preoperatively. To
date, surgical resection has proven most successful in
preventing recurrences. Only one case of local recur-
rence for extranodal soft tissue RDD following surgical
resection has been reported. However, as in the current
case, bilateral disease presentation is also possible and re-
quires close clinical follow-up. Given the rarity and indo-
lence of RDD, surveillance cannot be endorsed; however,
it is important to consider extranodal soft tissue RDD
amongst the differential diagnosis of patients presenting
with suspicious soft tissue masses. Future studies may
help to elucidate the natural history of this disease
process, as well as the possibility for malignant potential,
thus permitting the development of more evidence-based
treatment strategies. Until then, known RDD lesions
should be excised using established surgical principles.
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